Ticker LaunchIPO · BMEA
Biomea Fusion, Inc.
Biomea Fusion, Inc. (BMEA) priced its initial public offering on Apr 19, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $153M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $489.1M. J.P. Morgan was lead-left underwriter. Cooley advised the underwriters.
- Status
- IPO
- Ticker
- BMEA
- Exchange
- Nasdaq Global Select
- Priced
- Apr 19, 2021
- IPO price
- $17.00
- Price range
- $15.00–$17.00
- Raised
- $153M
- Market cap at IPO price
- $489.1M
- First filed
- Mar 26, 2021
- Underwriters
- J.P. Morgan
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Mar 26, 2021
- Latest amendment Apr 15, 2021
- Final prospectus (424B4) Apr 19, 2021
- All filings on EDGAR CIK 1840439
Other Biotech & pharma IPOs in 2021
- Zymergen Inc.ZY · Apr 23, 2021
- IPI Legacy Liquidation CoIMPL · Apr 23, 2021 · $80M
- Rain Oncology Inc.RAIN · Apr 23, 2021 · $125M
- Recursion Pharmaceuticals, Inc.RXRX · Apr 16, 2021 · $436.4M
- VectivBio Holding AGVECT · Apr 9, 2021 · $127.5M
- OnKure Therapeutics, Inc.RPHM · Apr 9, 2021 · $93.8M